Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 526 - 550 of 14772 in total

Amitriptyline

Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Approved
Matched Description: … ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961 …
Matched Mixtures name: … Perphenazine and Amitriptyline Hydrochloride ... Perphenazine and Amitriptyline Hydrochloride ... Chlordiazepoxide and Amitriptyline HCl …
Matched Categories: … amitriptyline and psycholeptics ... Antidepressive Agents ... Antidepressive Agents, Tricyclic ... Tricyclics and Other Norepinephrine-reuptake Inhibitors ... Antidepressive Agents Indicated for Depression …

Ubrogepant

Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... [A189207] Ubrogepant was approved by Health Canada on November 10, 2022. ... peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. ... [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ. ... [L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. …
Matched Categories: … Hypnotics and Sedatives …

Estradiol valerate

Estradiol Valerate (also known as E2V) is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore...
Approved
Investigational
Vet approved
Matched Description: … Because of the difference in potency between estradiol and estrone, menopause (and a change in primary ... a chance to enter systemic circulation and exert its estrogenic effects [A12102]. ... Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex …
Matched Mixtures name: … Estradiol Valerate and Estradiol Valerate/Dienogest ... Estradiol Valerate and Estradiol Valerate/Dienogest ... Estradiol Valerate and Estradiol Valerate/Dienogest …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Flosequinan

Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Approved
Withdrawn
Matched Description: … Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due …

Nilutamide

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. ... the growth of normal and malignant prostatic tissue. ... Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Olsalazine

Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works...
Approved
Matched Description: … [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase ... Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). ... , subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene …
Matched Categories: … Alimentary Tract and Metabolism …

Simeprevir

Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Description: … antiviral agent against the hepatitis C virus. ... Simeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral ... This class of antiviral drugs were the first direct acting antivirals approved but are associated with …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Imipenem

Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ertapenem which exhibits...
Approved
Matched Description: … product with cilastatin and [relebactam] which was recently approved by the FDA. ... Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed ... gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. …
Matched Mixtures name: … Imipenem and Cilastatin ... Imipenem and Cilastatin ... Imipenem and Cilastatin …
Matched Categories: … imipenem and cilastatin ... imipenem, cilastatin and relebactam …

Resmetirom

Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD). Thyroid hormones directly regulate lipid metabolism in the liver;...
Approved
Investigational
Matched Description: … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic ... [A263461] Resmetirom works to reduce liver fat by stimulating fatty acid degradation and oxidation. …

Bumadizone

Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout . Its use is restricted to these conditions, due to risks this drug poses .
Approved
Matched Description: … Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic ... , and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis and gout …
Matched Categories: … Acetic Acid Derivatives and Related Substances ... Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Cortisone acetate

Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] Cortisone acetate...
Approved
Investigational
Matched Description: … gastrointestinal diseases and disorders. ... Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. ... rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Emtricitabine

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of...
Approved
Investigational
Matched Description: … combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and …
Matched Mixtures name: … Emtricitabine and Tenofovir Disoproxil Fumarate ... Emtricitabine and Tenofovir Disoproxil Fumarate ... Emtricitabine and Tenofovir Disoproxil Fumarate …
Matched Categories: … tenofovir disoproxil and emtricitabine ... emtricitabine and tenofovir alafenamide ... Nucleic Acids, Nucleotides, and Nucleosides ... emtricitabine, tenofovir disoproxil and efavirenz ... emtricitabine, tenofovir disoproxil and rilpivirine …

Finafloxacin

Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
Approved
Investigational
Matched Description: … Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December ... the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and …

Oxolamine

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Description: … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422]. ... Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant …
Matched Categories: … Cough and Cold Preparations …

Taliglucerase alfa

Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Drotaverine

Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] ... [A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. ... [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour …
Matched Categories: … Alimentary Tract and Metabolism ... Papaverine and Derivatives …

Relugolix

Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name...
Approved
Investigational
Matched Description: … [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and ... It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment ... of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... relugolix, estradiol and norethisterone …

Thiethylperazine

A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Approved
Withdrawn
Matched Description: … anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. ... A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with …

Hydroxyprogesterone caproate

Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug...
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999.[L46118] The U.S. ... FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention ... Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved …
Matched Categories: … Progesterone and Derivatives ... Combination Contraceptives (with Estrogen and derivatives) ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Moxidectin

Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of...
Approved
Investigational
Vet approved
Matched Description: … [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June ... It was first used in cattle followed by an approved use in general animals. ... ) with activity against nematodes, insects, and acari. …
Matched Mixtures name: … Advocate Spot-on Solution for Small Cats and Ferrets …
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …

Linezolid

Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically,...
Approved
Investigational
Matched Description: … Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class ... [A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered ... Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most …
Matched Categories: … Antidepressive Agents …

Pindolol

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s....
Approved
Investigational
Matched Description: … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation …
Matched Categories: … Antidepressive Agents ... pindolol and other diuretics …

LetibotulinumtoxinA

The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when onabotulinumtoxinA (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial...
Approved
Matched Description: … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since ... was subsequently approved in the European Union. ... ] and in the US in March 2024. …

Remoxipride

Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Description: … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. …
Matched Categories: … Benzamides and benzamide derivatives …
Displaying drugs 526 - 550 of 14772 in total